Matthew D. Galsky

34.4k total citations · 6 hit papers
393 papers, 13.2k citations indexed

About

Matthew D. Galsky is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Matthew D. Galsky has authored 393 papers receiving a total of 13.2k indexed citations (citations by other indexed papers that have themselves been cited), including 216 papers in Surgery, 177 papers in Oncology and 151 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Matthew D. Galsky's work include Bladder and Urothelial Cancer Treatments (207 papers), Urinary and Genital Oncology Studies (139 papers) and Cancer Immunotherapy and Biomarkers (89 papers). Matthew D. Galsky is often cited by papers focused on Bladder and Urothelial Cancer Treatments (207 papers), Urinary and Genital Oncology Studies (139 papers) and Cancer Immunotherapy and Biomarkers (89 papers). Matthew D. Galsky collaborates with scholars based in United States, Italy and France. Matthew D. Galsky's co-authors include William Oh, Guru Sonpavde, Vaibhav G. Patel, Noah M. Hahn, Nicholas J. Vogelzang, Joaquim Bellmunt, Andrea Necchi, Padmanee Sharma, Dean F. Bajorin and Cora N. Sternberg and has published in prestigious journals such as Cell, JAMA and Journal of Biological Chemistry.

In The Last Decade

Matthew D. Galsky

370 papers receiving 13.0k citations

Hit Papers

Nivolumab in metastatic u... 2011 2026 2016 2021 2017 2020 2011 2019 2017 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
    2017 1.2k citations Padmanee Sharma, Arlene O. Siefker‐Radtke et al. profile →
  2. Treatment of muscle‐invasive and advanced bladder cancer in 2020
    2020 693 citations Vaibhav G. Patel, William Oh et al. profile →
  3. Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
    2011 457 citations Matthew D. Galsky, Noah M. Hahn et al. Journal of Clinical Oncology profile →
  4. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
    2019 435 citations Peter H. O’Donnell, Matthew D. Galsky et al. Journal of Clinical Oncology profile →
  5. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity
    2017 288 citations Matthew D. Galsky, Matthew I. Milowsky et al. profile →
  6. Bladder cancer
    2023 212 citations Matthew D. Galsky et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matthew D. Galsky United States 55 6.5k 5.6k 3.8k 3.3k 1.6k 393 13.2k
Guru Sonpavde United States 53 6.5k 1.0× 6.9k 1.2× 5.1k 1.3× 3.3k 1.0× 2.3k 1.4× 628 15.1k
Noah M. Hahn United States 44 5.7k 0.9× 4.4k 0.8× 4.5k 1.2× 2.2k 0.7× 1.6k 1.0× 261 11.4k
Yves Fradet Canada 65 8.7k 1.3× 4.8k 0.9× 5.2k 1.4× 3.4k 1.0× 1.9k 1.2× 376 16.1k
Matthew I. Milowsky United States 51 5.4k 0.8× 3.2k 0.6× 3.5k 0.9× 2.7k 0.8× 1.1k 0.7× 274 10.2k
Dean F. Bajorin United States 73 15.6k 2.4× 8.0k 1.4× 4.9k 1.3× 4.2k 1.3× 1.4k 0.9× 492 21.4k
Brent A. Blumenstein United States 40 3.2k 0.5× 3.9k 0.7× 5.6k 1.5× 2.8k 0.9× 1.9k 1.2× 123 12.0k
Sam S. Chang United States 45 4.9k 0.8× 2.4k 0.4× 3.1k 0.8× 2.2k 0.7× 861 0.5× 209 9.9k
Ashish M. Kamat United States 69 13.3k 2.1× 4.6k 0.8× 3.2k 0.8× 4.1k 1.3× 1.5k 0.9× 540 18.8k
Seth P. Lerner United States 66 12.6k 1.9× 3.6k 0.6× 3.0k 0.8× 4.0k 1.2× 1.7k 1.1× 375 16.4k
Derek Raghavan United States 50 8.9k 1.4× 6.6k 1.2× 7.1k 1.9× 3.2k 1.0× 3.1k 2.0× 296 19.1k

Countries citing papers authored by Matthew D. Galsky

Since Specialization
Citations

This map shows the geographic impact of Matthew D. Galsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew D. Galsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew D. Galsky more than expected).

Fields of papers citing papers by Matthew D. Galsky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew D. Galsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew D. Galsky. The network helps show where Matthew D. Galsky may publish in the future.

Co-authorship network of co-authors of Matthew D. Galsky

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew D. Galsky. A scholar is included among the top collaborators of Matthew D. Galsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew D. Galsky. Matthew D. Galsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Powles, Thomas, Enrique Grande, Nimira Alimohamed, et al.. (2025). SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma. Future Oncology. 21(21). 2705–2712. 1 indexed citations
2.
Galsky, Matthew D., Che‐Kai Tsao, Kyrollis Attalla, et al.. (2025). Clinical utility of tumour‐informed circulating tumour DNA in patients with testicular cancer. British Journal of Urology. 136(6). 1098–1106. 1 indexed citations
3.
4.
Galsky, Matthew D., John P. Sfakianos, Dingwei Ye, et al.. (2025). Phase II study of oral APL-1202 plus tislelizumab or tislelizumab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology. 43(5_suppl). 793–793. 1 indexed citations
5.
Gao, Xin, Amita Patnaik, Nehal J. Lakhani, et al.. (2025). NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors.. Journal of Clinical Oncology. 43(5_suppl). 2 indexed citations
6.
Simon, Nicholas I., Stephanie Berg, Alan Tan, et al.. (2025). Preferred treatment regimens for rare genitourinary (GU) malignancies.. Journal of Clinical Oncology. 43(5_suppl). 780–780.
7.
Anker, Jonathan F., et al.. (2024). Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient. American Society of Clinical Oncology Educational Book. 44(3). e432054–e432054. 4 indexed citations
8.
Patel, Vaibhav G., Deepak Kumar Singh, Himanshu Joshi, et al.. (2024). Abstract CT223: Dormancy reprograming therapy of 5-azacitidine (AZA) and all-trans retinoic acid (ATRA) in biochemically recurrent prostate cancer. Cancer Research. 84(7_Supplement). CT223–CT223. 2 indexed citations
9.
Damrauer, Jeffrey S., Jeffrey A. Klomp, Mi Zhou, et al.. (2022). Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nature Communications. 13(1). 6658–6658. 27 indexed citations
10.
Fallara, Giuseppe, Federico Belladelli, Daniele Robesti, et al.. (2022). Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 179. 103801–103801. 3 indexed citations
11.
Galsky, Matthew D., Christopher Hoimes, Andrea Necchi, et al.. (2021). Perioperative Pembrolizumab Therapy in Muscle-Invasive Bladder Cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. Future Oncology. 17(24). 3137–3150. 38 indexed citations
12.
Rouanne, Mathieu, Dean F. Bajorin, Raquibul Hannan, et al.. (2020). Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. European Urology Oncology. 3(6). 728–738. 57 indexed citations
13.
Goswami, Sangeeta, Yulong Chen, Swetha Anandhan, et al.. (2020). ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Science Translational Medicine. 12(548). 92 indexed citations
14.
Galsky, Matthew D., Abdel Saci, Péter M. Szabó, et al.. (2020). Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275. Clinical Cancer Research. 26(19). 5120–5128. 83 indexed citations
15.
Sfakianos, John P., Jorge Daza, Yang Hu, et al.. (2020). Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers. Nature Communications. 11(1). 2540–2540. 40 indexed citations
16.
Gong, Yixuan, Li Wang, Naomi Alpert, et al.. (2019). Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade. Molecular Cancer Research. 17(8). 1605–1612. 20 indexed citations
17.
Lin, Jenny J., Emily J. Gallagher, Keith Sigel, et al.. (2014). Survival of Patients with Stage IV Lung Cancer with Diabetes Treated with Metformin. American Journal of Respiratory and Critical Care Medicine. 191(4). 448–454. 113 indexed citations
18.
Meeks, Joshua J., Joaquim Bellmunt, Bernard H. Bochner, et al.. (2012). A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology. 62(3). 523–533. 168 indexed citations
19.
Galsky, Matthew D., Luis H. Camacho, E. Gabriela Chiorean, et al.. (2011). Retrospective Analysis of Satraplatin in Patients with Metastatic Urothelial Cancer Refractory to Standard Platinum-Based Chemotherapy. Clinical Genitourinary Cancer. 9(1). 27–30. 4 indexed citations
20.
Galsky, Matthew D., Daniel D. Von Hoff, Marcus A. Neubauer, et al.. (2010). Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Investigational New Drugs. 30(2). 695–701. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guru Sonpavde Breakdown of academic impact, for papers by Noah M. Hahn Breakdown of academic impact, for papers by Yves Fradet Breakdown of academic impact, for papers by Matthew I. Milowsky Breakdown of academic impact, for papers by Dean F. Bajorin Breakdown of academic impact, for papers by Brent A. Blumenstein Breakdown of academic impact, for papers by Sam S. Chang Breakdown of academic impact, for papers by Ashish M. Kamat Breakdown of academic impact, for papers by Seth P. Lerner Breakdown of academic impact, for papers by Derek Raghavan
Rankless by CCL
2026